Ultragenyx Pharmaceutical Inc. buy Barclays PLC
Start price
06.08.24
/
50%
€45.20
Target price
06.08.25
€74.24
Performance (%)
-48.67%
End price
07.08.25
€23.20
Summary
This prediction ended on 07.08.25 with a price of €23.20. Massive losses of -48.67% were the result for the BUY prediction by Barclays_PLC. Barclays_PLC has a follow-up prediction for Ultragenyx Pharmaceutical Inc. where he still thinks Ultragenyx Pharmaceutical Inc. is a Buy. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 4.873% | 4.873% | -33.355% |
| iShares Core DAX® | 3,59 % | 3,93 % | 15,38 % |
| iShares Nasdaq 100 | 5,81 % | 5,52 % | 41,46 % |
| iShares Nikkei 225® | 4,08 % | 8,46 % | 48,95 % |
| iShares S&P 500 | 4,14 % | 4,04 % | 31,59 % |
Comments by Barclays_PLC for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Barclays PLC from $83.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Barclays_PLC gewählte maximale Laufzeit wurde überschritten
Current prediction by Barclays_PLC for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€28.40
24.11.25
24.11.25
€43.44
24.11.26
24.11.26
-25.70%
17.04.26
17.04.26
